Acquired hemophilia masked by warfarin therapy

American Journal of the Medical Sciences

Volumn 319, Issue 3, 2000, Pages 197-201

  Kantor, Rami ^a   Mayan, Haim ^a   Puritz, Lena ^a   Varon, David ^a,b   Farfel, Zvi ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Acquired hemophilia; Factor VIII; Partial thromboblastin time (PTT); Warfarin

Indexed keywords

ANTICOAGULANT AGENT; AUTOANTIBODY; BLOOD CLOTTING FACTOR 8; WARFARIN;

AGED; ARTICLE; CASE REPORT; DIAGNOSTIC APPROACH ROUTE; EARLY DIAGNOSIS; FEMALE; HEMOPHILIA; HUMAN; LABORATORY DIAGNOSIS; PARTIAL THROMBOPLASTIN TIME;

EID: 0034089530     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200003000-00013     Document Type: Article

References (27)

1. Sultan Y. Acquired hemophilia and its treatment. Blood Coagul Fibrinolysis 1997;8 Suppl:S15-8.
2. Handin RI. Disorders of coagulation and thrombosis In: Fauci AS, Braunwald E, Isselbacher KJ, et al, editors. Harrison's principles of internal medicine. 14th ed. New York: McGraw Hill; 1998. p. 741.
3. Hutlin B. Acquired inhibitors in malignant and nonmalignant disease states. Am J Med 1991;91(Suppl 5A):9S-13S.
4. Lottenberg R, Kentro TB, Kitchens CS. Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med 1987;147:1077-81.
5. Hoyer LW. Acquired anticoagulants. In: Beutler E, Lichtman MA, Coller BS, et al, editors. Williams hematology. 5th ed. New York: McGraw-Hill; 1995. p. 1486-9.
6. Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost 1981; 45:200-3.
7. Hoyer LW. Factor VIII inhibitors. Curr Opin Hematol 1995; 2:365-71.
8. Kessler CM, Ludlam CA. The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. Semin Hematol 1993;30 Suppl:22-7.
9. Shaffer LG, Phillips MD. Successful treatment of acquired hemophilia with oral immunosupressive therapy. Ann Intern Med 1997;127:206-9.
10. Ludlam CA, Morrison AE, Kessler C. Treatment of acquired hemophilia. Semin Hematol 1994;31 Suppl:16-9.
11. Kessler CM. An introduction to factor VIII inhibitors: the detection and quantitation. Am J Med 1991;91(suppl 5A):1S-5S.
12. Kessler CM. Conclusion. Am J Med 1991;91(suppl 5A):45S-47S.
13. Steinbrueckner B, Steigerwald U, Keller F, et al. Atypical spontaneous factor VIII inhibitor: specific diagnostics and therapy of acute bleeding. Acta Haematol 1998;99:102-5.
14. Wallach J. Interpretation of Diagnostic Tests. 6th ed. Boston: Little, Brown and Company; 1996. p. 421-3.
15. Goldsmith JC. Diagnosis of factor VIII versus nonspecific inhibitors. Semin Hematol 1993;30 Suppl:3-6.
16. Ellenhorn MJ, Schonwald S, Ordog G, et al. Ellenhorn's Medical Toxicology. 2nd ed. Baltimore, Maryland: Williams & Wilkins; 1997. p. 452-60.
17. Handin RI. Bleeding and Thrombosis. In: Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, et al. eds; Harrison's Principles of Internal Medicine. 14th ed. New York: McGraw Hill; 1998. p. 344.
18. Kearon C, Johnston M, Moffat K, et al. Effect of warfarin on activated partial thromboplastin time in patients receiving heparin. Arch Intern Med 1998;158:1140-3.
19. Mungall D, Floyd R. Bayesian forecasting of APTT response to continuously infused heparin with and without warfarin administration. J Clin Pharmacol 1989;29:1043-7.
20. Hauser VM, Rozek SL. Effect of warfarin on the activated partial thromboplastin time. Drug Intell Clin Pharm 1986; 20:964-7.
21. Majerus PW, Broze Jr. GJ, Miletich JP, et al. Anticoagulant, thrombolytic, and antiplatelet drugs. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman Gilman A; eds. Goodman & Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996. p. 1341-60.
22. Hirsh J, Dalen JE, Deykin D, et al. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1995;108 Suppl:231S-6S.
23. Sultan Y, Algiman KM, Dietrich G, et al. The use of intravenous immunoglobulin in the treatment of factor VIII inhibitors. Semin Hematol 1994;31 Suppl:65-6.
24. Green D. Immunosuppression of factor VIII inhibitors in nonhemophilic patients. Semin Hematol 1993;30 Suppl:28-31.
25. Bona RD, Riberio M, Klatsky AU, et al. Continuous infusion of porcine factor VIII for the treatment of patients with factor VIII inhibitors. Semin Hematol 1993;30 Suppl:32-5.
26. Morrison AE, Ludlam CA. The use of porcine factor VIII in the treatment of patients with acquired hemophilia: the United Kingdom experience. Am J Med 1991;91(suppl 5A): 23S-6S.
27. Schulman S, Langevitz P, Livneh A, et al. Cyclosporine therapy for acquired factor VIII inhibitor in a patient with systemic lupus erythematosus. Thromb Haemost 1996;76: 344-6.